Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 2.6%

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) were down 2.6% during mid-day trading on Tuesday . The company traded as low as $2.96 and last traded at $2.98. Approximately 263,309 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 2,767,350 shares. The stock had previously closed at $3.06.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TSHA shares. JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Chardan Capital increased their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 21st. Needham & Company LLC increased their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $6.57.

Taysha Gene Therapies Stock Performance

The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54. The stock has a 50 day simple moving average of $2.15 and a two-hundred day simple moving average of $2.13.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently made changes to their positions in TSHA. FMR LLC boosted its holdings in Taysha Gene Therapies by 2,035.0% in the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after purchasing an additional 23,378,974 shares in the last quarter. RA Capital Management L.P. acquired a new position in Taysha Gene Therapies in the 3rd quarter worth $58,373,000. RTW Investments LP acquired a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at about $53,382,000. Acuta Capital Partners LLC acquired a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at about $12,096,000. Finally, Vanguard Group Inc. raised its stake in shares of Taysha Gene Therapies by 235.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock valued at $16,836,000 after purchasing an additional 3,738,616 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.